While October's COLA announcement brings temporary relief, a growing body of evidence suggests the formula used to calculate Social Security adjustments fails to reflect the real-world expenses of retirees, creating a persistent and compounding budget gap.
The U.S. Securities and Exchange Commission has ushered in a new era for the accounting watchdog, naming a fresh chair and three board members tasked with refocusing the PCAOB on its core mission of investor protection.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Despite Dell Technologies' strategic push into AI infrastructure and analyst endorsements, its stock continues to underperform the broader market, raising questions about the timing of its promised turnaround.
Forty years after Reagan and Gorbachev's historic meeting in Iceland envisioned a world free of nuclear weapons, expired treaties, rising stockpiles, and new global players are fueling a dangerous relapse.
Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.
Conagra Brands launches its protein-packed Banquet MEGA Breakfast Bowls, a direct challenge to rivals in the frozen aisle. While the move aligns with consumer trends, analysts question if it's enough to offset broader financial pressures facing the packaged food giant.
Lucid Air Grand Touring secures the top spot in a grueling Nordic winter range test, providing a much-needed technical validation for the luxury EV maker amidst a challenging market climate.
As Bob Iger prepares for his second departure, the Disney CEO outlines a forward-looking mandate for his successor during an earnings call, emphasizing evolution in a dynamic media landscape.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.
FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
As Bob Iger prepares to step down, he highlights a 'healthy competition' between Disney's resurgent parks and its entertainment division to become the company's primary profit driver, with the board close to naming his successor.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
